Ambikanandan Misra

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6750164/publications.pdf

Version: 2024-02-01

158 papers

7,261 citations

66234 42 h-index 80 g-index

162 all docs

162 docs citations

times ranked

162

9487 citing authors

#	Article	IF	CITATIONS
1	PEG â€" A versatile conjugating ligand for drugs and drug delivery systems. Journal of Controlled Release, 2014, 192, 67-81.	4.8	494
2	Epidermal growth factor receptor targeting in cancer: A review of trends and strategies. Biomaterials, 2013, 34, 8690-8707.	5.7	408
3	Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. International Journal of Pharmaceutics, 2008, 358, 285-291.	2.6	380
4	The intracellular drug delivery and anti tumor activity of doxorubicin loaded poly(γ-benzyl) Tj ETQq0 0 0 rgBT /O	verlock 10 5.7	Tf 50 622 Td
5	Drug delivery to the central nervous system: a review. Journal of Pharmacy and Pharmaceutical Sciences, 2003, 6, 252-73.	0.9	297
6	Modification of theophylline release with alginate gel formed in hard capsules. AAPS PharmSciTech, 2007, 8, E1-E8.	1.5	235
7	Intranasal Drug Delivery for Brain Targeting. Current Drug Delivery, 2005, 2, 165-175.	0.8	206
8	Biomimetic Doxorubicin Loaded Polymersomes from Hyaluronan- <i>block</i> -Poly(γ-benzyl glutamate) Copolymers. Biomacromolecules, 2009, 10, 2802-2808.	2.6	195
9	Role of Caco-2 Cell Monolayers in Prediction of Intestinal Drug Absorption. Biotechnology Progress, 2006, 22, 186-198.	1.3	190
10	Intranasal Mucoadhesive Microemulsions of Clonazepam: Preliminary Studies on Brain Targeting. Journal of Pharmaceutical Sciences, 2006, 95, 570-580.	1.6	148
11	Mucoadhesive nanoemulsion-based intranasal drug delivery system of olanzapine for brain targeting. Journal of Drug Targeting, 2008, 16, 806-814.	2.1	147
12	Targeted delivery of monoclonal antibody conjugated docetaxel loaded PLGA nanoparticles into EGFR overexpressed lung tumour cells. Journal of Microencapsulation, 2018, 35, 204-217.	1.2	123
13	Liposomes encapsulating native and cyclodextrin enclosed paclitaxel: Enhanced loading efficiency and its pharmacokinetic evaluation. International Journal of Pharmaceutics, 2018, 536, 95-107.	2.6	119
14	Intranasal Mucoadhesive Microemulsion of Tacrine to Improve Brain Targeting. Alzheimer Disease and Associated Disorders, 2008, 22, 116-124.	0.6	106
15	Systematic Approach for the Formulation and Optimization of Solid Lipid Nanoparticles of Efavirenz by High Pressure Homogenization Using Design of Experiments for Brain Targeting and Enhanced Bioavailability. BioMed Research International, 2017, 2017, 1-18.	0.9	106
16	Formulation and Characterization of Nanoemulsion-Based Drug Delivery System of Risperidone. Drug Development and Industrial Pharmacy, 2009, 35, 387-395.	0.9	101
17	Intranasal mucoadhesive microemulsions of zolmitriptan: Preliminary studies on brain-targeting. Journal of Drug Targeting, 2005, 13, 317-324.	2.1	97
18	Topical Amphotericin B solid lipid nanoparticles: Design and development. Colloids and Surfaces B: Biointerfaces, 2016, 139, 17-24.	2.5	96

#	Article	IF	Citations
19	Amphotericin B topical microemulsion: Formulation, characterization and evaluation. Colloids and Surfaces B: Biointerfaces, 2014, 116, 351-358.	2.5	95
20	Recent Patents Review on Intranasal Administration for CNS Drug Delivery. Recent Patents on Drug Delivery and Formulation, 2008, 2, 25-40.	2.1	94
21	Preliminary brain-targeting studies on intranasal mucoadhesive microemulsions of sumatriptan. AAPS PharmSciTech, 2006, 7, E49-E57.	1.5	85
22	Development of Spray Dried Liposomal Dry Powder Inhaler of Dapsone. AAPS PharmSciTech, 2008, 9, 47-53.	1.5	84
23	The in vivo behavior and antitumor activity of doxorubicin-loaded poly(\hat{I}^3 -benzyl) Tj ETQq1 1 0.784314 rgBT /Ove Nanomedicine: Nanotechnology, Biology, and Medicine, 2012, 8, 71-80.	erlock 10 T 1.7	f 50 587 To 80
24	Recent advances in liposomal dry powder formulations: preparation and evaluation. Expert Opinion on Drug Delivery, 2009, 6, 71-89.	2.4	79
25	Proteins: emerging carrier for delivery of cancer therapeutics. Expert Opinion on Drug Delivery, 2013, 10, 1429-1448.	2.4	74
26	Protein– and Peptide–Drug Conjugates. Advances in Protein Chemistry and Structural Biology, 2015, 98, 1-55.	1.0	73
27	In vitro and In vivo Evaluation of Docetaxel Loaded Biodegradable Polymersomes. Macromolecular Bioscience, 2010, 10, 503-512.	2.1	70
28	Dry powder inhalation of liposomal Ketotifen fumarate: formulation and characterization. International Journal of Pharmaceutics, 2001, 223, 15-27.	2.6	68
29	Development of Dry Powder Inhalers. Recent Patents on Drug Delivery and Formulation, 2007, 1, 11-21.	2.1	65
30	Drug Delivery Systems from Nose to Brain. Current Pharmaceutical Biotechnology, 2012, 13, 2355-2379.	0.9	61
31	Liposomal formulations of Etoposide and Docetaxel for p53 mediated enhanced cytotoxicity in lung cancer cell lines. Biomaterials, 2012, 33, 2492-2507.	5.7	59
32	In Vivo Delivery Aspects of miRNA, shRNA and siRNA. Critical Reviews in Therapeutic Drug Carrier Systems, 2012, 29, 487-527.	1.2	56
33	Nano-liposomal dry powder inhaler of tacrolimus: preparation, characterization, and pulmonary pharmacokinetics. International Journal of Nanomedicine, 2007, 2, 675-88.	3.3	56
34	Topical Liposomal Gel of Tretinoin for the Treatment of Acne: Research and Clinical Implications. Pharmaceutical Development and Technology, 2000, 5, 455-464.	1.1	54
35	cRGD grafted liposomes containing inorganic nano-precipitate complexed siRNA for intracellular delivery in cancer cells. Journal of Controlled Release, 2014, 182, 45-57.	4.8	52
36	Preparation of PEGylated liposomes of docetaxel using supercritical fluid technology. Journal of Supercritical Fluids, 2010, 54, 110-119.	1.6	51

#	Article	IF	CITATIONS
37	Receptor-targeted drug delivery: current perspective and challenges. Therapeutic Delivery, 2014, 5, 1007-1024.	1.2	51
38	Development and Characterization of siRNA Lipoplexes: Effect of Different Lipids, In Vitro Evaluation in Cancerous Cell Lines and In Vivo Toxicity Study. AAPS PharmSciTech, 2014, 15, 1630-1643.	1.5	51
39	PEGylated composite nanoparticles of PLGA and polyethylenimine for safe and efficient delivery of pDNA to lungs. International Journal of Pharmaceutics, 2017, 524, 382-396.	2.6	48
40	Improved Transnasal Transport and Brain Uptake of Tizanidine HCl-Loaded Thiolated Chitosan Nanoparticles for Alleviation of Pain. Journal of Pharmaceutical Sciences, 2012, 101, 690-706.	1.6	47
41	Preparation and Comparative Clinical Evaluation of Liposomal Gel of Benzoyl Peroxide for Acne. Drug Development and Industrial Pharmacy, 2001, 27, 863-870.	0.9	46
42	Topical Liposomal Gel of Idoxuridine for the Treatment of Herpes Simplex: Pharmaceutical and Clinical Implications. Pharmaceutical Development and Technology, 2005, 9, 277-289.	1.1	46
43	Liposomal amikacin dry powder inhaler: Effect of fines on in vitro performance. AAPS PharmSciTech, 2004, 5, 107-113.	1.5	45
44	Role of Block Copolymer Nanoconstructs in Cancer Therapy. Critical Reviews in Therapeutic Drug Carrier Systems, 2009, 26, 157-205.	1,2	45
45	Lipid-Based Oral Formulation Strategies for Lipophilic Drugs. AAPS PharmSciTech, 2018, 19, 3609-3630.	1.5	44
46	Triple negative breast cancer and non-small cell lung cancer: Clinical challenges and nano-formulation approaches. Journal of Controlled Release, 2021, 337, 27-58.	4.8	44
47	Lipid-nucleic acid nanoparticles of novel ionizable lipids for systemic BMP-9 gene delivery to bone-marrow mesenchymal stem cells for osteoinduction. International Journal of Pharmaceutics, 2019, 563, 324-336.	2.6	43
48	Role of antibodies in diagnosis and treatment of ovarian cancer: Basic approach and clinical status. Journal of Controlled Release, 2016, 226, 148-167.	4.8	42
49	Macromol. Biosci. 5/2010. Macromolecular Bioscience, 2010, 10, .	2.1	41
50	Development of Liposomal Amphotericin B Dry Powder Inhaler Formulation. Drug Delivery, 2004, 11, 247-253.	2.5	40
51	In vitro mechanistic study of cell death and in vivo performance evaluation of RGD grafted PEGylated docetaxel liposomes in breast cancer. Nanomedicine: Nanotechnology, Biology, and Medicine, 2012, 8, 951-962.	1.7	40
52	Inhalable liposomal dry powder of gemcitabine-HCl: Formulation, in vitro characterization and in vivo studies. International Journal of Pharmaceutics, 2015, 496, 886-895.	2.6	39
53	Nose-to-brain delivery of tacrine. Journal of Pharmacy and Pharmacology, 2010, 59, 1199-1205.	1.2	37
54	Combinatorial nanocarriers against drug resistance in hematological cancers: Opportunities and emerging strategies. Journal of Controlled Release, 2019, 296, 114-139.	4.8	36

#	Article	IF	CITATIONS
55	Comparative Receptor Based Brain Delivery of Tramadol-Loaded Poly(lactic-co-glycolic acid) Nanoparticles. Journal of Biomedical Nanotechnology, 2012, 8, 918-927.	0.5	35
56	Low molecular weight chitosan–protamine conjugate for siRNA delivery with enhanced stability and transfection efficiency. RSC Advances, 2016, 6, 110951-110963.	1.7	35
57	Docetaxel loaded immunonanoparticles delivery in EGFR overexpressed breast carcinoma cells. Journal of Drug Delivery Science and Technology, 2018, 45, 334-345.	1.4	35
58	Brain targeted intranasal delivery of tramadol: comparative study of microemulsion and nanoemulsion. Pharmaceutical Development and Technology, 2015, 20, 992-1001.	1.1	34
59	A preliminary pharmacokinetic study of liposomal leuprolide dry powder inhaler: A technical note. AAPS PharmSciTech, 2005, 6, E482-E486.	1.5	33
60	Polymeric Micelle as Multifunctional Pharmaceutical Carriers. Journal of Nanoscience and Nanotechnology, 2014, 14, 288-307.	0.9	33
61	Microbeads mediated oral plasmid DNA delivery using polymethacrylate vectors: an effectual groundwork for colorectal cancer. Drug Delivery, 2015, 22, 849-861.	2.5	33
62	Protein-Functionalized PLGA Nanoparticles of Lamotrigine for Neuropathic Pain Management. AAPS PharmSciTech, 2015, 16, 413-427.	1.5	31
63	Nano-Liposomal Dry Powder Inhaler of Amiloride Hydrochloride. Journal of Nanoscience and Nanotechnology, 2006, 6, 3001-3009.	0.9	30
64	Intranasal delivery of cyclobenzaprine hydrochloride-loaded thiolated chitosan nanoparticles for pain relief. Journal of Drug Targeting, 2013, 21, 759-769.	2.1	30
65	Protein functionalized tramadol-loaded PLGA nanoparticles: preparation, optimization, stability and pharmacodynamic studies. Drug Development and Industrial Pharmacy, 2013, 39, 854-864.	0.9	30
66	Association of Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) and Thyroglobulin (TG) Genetic Variants with Autoimmune Hypothyroidism. PLoS ONE, 2016, 11, e0149441.	1.1	30
67	Colloidally Stable Small Unilamellar Stearyl Amine Lipoplexes for Effective BMP-9 Gene Delivery to Stem Cells for Osteogenic Differentiation. AAPS PharmSciTech, 2018, 19, 3550-3560.	1.5	29
68	Nasal delivery of levonorgestrel for contraception: an experimental study in rats. Fertility and Sterility, 2004, 81, 893-898.	0.5	28
69	Modulation of Ganciclovir Intestinal Absorption in Presence of Absorption Enhancers. Journal of Pharmaceutical Sciences, 2007, 96, 2710-2722.	1.6	28
70	Synergistic co-loading of vincristine improved chemotherapeutic potential of pegylated liposomal doxorubicin against triple negative breast cancer and non-small cell lung cancer. Nanomedicine: Nanotechnology, Biology, and Medicine, 2021, 31, 102320.	1.7	28
71	Disposition kinetics of ketotifen from liposomal dry powder for inhalation in rat lung. Clinical and Experimental Pharmacology and Physiology, 2003, 30, 153-156.	0.9	26
72	Microemulsion based intranasal delivery system for treatment of insomnia. Drug Delivery, 2009, 16, 128-134.	2.5	26

#	Article	IF	CITATIONS
73	Formulation and optimization of porous osmotic pump-based controlled release system of oxybutynin. AAPS PharmSciTech, 2007, 8, E13-E19.	1.5	25
74	Intranasal Cabergoline: Pharmacokinetic and Pharmacodynamic Studies. AAPS PharmSciTech, 2009, 10, 1321-30.	1.5	25
75	In Vitro Assessment of Acyclovir Permeation Across Cell Monolayers in the Presence of Absorption Enhancers. Drug Development and Industrial Pharmacy, 2008, 34, 279-288.	0.9	24
76	Hydroxyethyl substituted linear polyethylenimine for safe and efficient delivery of siRNA therapeutics. RSC Advances, 2018, 8, 35461-35473.	1.7	24
77	Gemini Amphiphiles: A Novel Class of Nonviral Gene Delivery Vectors. Critical Reviews in Therapeutic Drug Carrier Systems, 2010, 27, 237-278.	1.2	24
78	Role of Nanotechnology in Delivery of Protein and Peptide Drugs. Current Pharmaceutical Design, 2015, 21, 4155-4173.	0.9	24
79	Mucosal Immunization: A Review of Strategies and Challenges. Critical Reviews in Therapeutic Drug Carrier Systems, 2014, 31, 273-303.	1.2	23
80	Antimicrobial peptide delivery: an emerging therapeutic for the treatment of burn and wounds. Therapeutic Delivery, 2018, 9, 375-386.	1.2	23
81	Pulmonary absorption of liposomal levonorgestrel. AAPS PharmSciTech, 2004, 5, 96-100.	1.5	22
82	Abstract 2065: Anti-FSHR antibody Fab' fragment conjugated immunoliposomes loaded with cyclodextrin-paclitaxel complex for improved <i>in vitro</i> efficacy on ovarian cancer cells. Cancer Research, 2016, 76, 2065-2065.	0.4	22
83	Intracellular Delivery of Nanoparticles of an Antiasthmatic Drug. AAPS PharmSciTech, 2008, 9, 217-223.	1.5	21
84	Surface-modified Epirubicin-HCl liposomes and its <i>in vitro</i> assessment in breast cancer cell-line: MCF-7. Drug Delivery, 2016, 23, 1152-1162.	2.5	21
85	Nanoliposomal Dry Powder Formulations. Methods in Enzymology, 2009, 464, 167-191.	0.4	20
86	Co-delivery of cisplatin and siRNA through hybrid nanocarrier platform for masking resistance to chemotherapy in lung cancer. Drug Delivery and Translational Research, 2021, 11, 2052-2071.	3.0	19
87	Polymer-drug conjugates: Design principles, emerging synthetic strategies and clinical overview. International Journal of Pharmaceutics, 2022, 623, 121863.	2.6	19
88	Nanocarriers in effective pulmonary delivery of siRNA: current approaches and challenges. Therapeutic Delivery, 2019, 10, 311-332.	1.2	18
89	Optimization of Formulation Components and Characterization of Large Respirable Powders Containing High Therapeutic Payload. Pharmaceutical Development and Technology, 2006, 11, 465-475.	1.1	17
90	Preliminary investigation of the nasal delivery of liposomal leuprorelin acetate for contraception in ratsâ€. Journal of Pharmacy and Pharmacology, 2010, 58, 19-26.	1.2	17

#	Article	IF	Citations
91	Gene Delivery Using Physical Methods. , 2011, , 83-126.		17
92	Oral Delivery of Proteins and Peptides. , 2011, , 481-529.		17
93	Suppression of cytokine gene expression and improved therapeutic efficacy of microemulsion-based tacrolimus cream for atopic dermatitis. Drug Delivery and Translational Research, 2012, 2, 129-141.	3.0	17
94	Preparation and evaluation of hepatic stellate cell selective, surface conjugated, peroxisome proliferator-activated receptor-gamma ligand loaded liposomes. Journal of Drug Targeting, 2012, 20, 155-165.	2.1	16
95	Oral Absorption Promoters: Opportunities, Issues, and Challenges. Critical Reviews in Therapeutic Drug Carrier Systems, 2015, 32, 363-387.	1.2	16
96	Surface engineered liposomal delivery of therapeutics across the blood brain barrier: recent advances, challenges and opportunities. Expert Opinion on Drug Delivery, 2019, 16, 1287-1311.	2.4	15
97	New and novel approaches for enhancing the oral absorption and bioavailability of protein and peptides therapeutics. Therapeutic Delivery, 2020, 11, 713-732.	1.2	15
98	Development of voriconazole loaded large porous particles for inhalation delivery: effect of surface forces on aerosolisation performance, assessment of in vitro safety potential and uptake by macrophages. RSC Advances, 2015, 5, 38030-38043.	1.7	14
99	Challenges in Dermal Delivery of Therapeutic Antimicrobial Protein and Peptides. Current Drug Metabolism, 2017, 18, 426-436.	0.7	14
100	Pharmaceutical Development of Solid Dispersion Based Osmotic Drug Delivery System for Nifedipine. Current Drug Delivery, 2008, 5, 306-311.	0.8	14
101	Antisense Oligonucleotides and RNA Interference. , 2011, , 325-386.		13
102	Targeted drug therapy in nonsmall cell lung cancer: clinical significance and possible solutions-part II (role of nanocarriers). Expert Opinion on Drug Delivery, 2021, 18, 103-118.	2.4	13
103	Targeted drug therapy in non-small cell lung cancer: Clinical significance and possible solutions-Part I. Expert Opinion on Drug Delivery, 2021, 18, 73-102.	2.4	13
104	Liposomes and Lipid Envelope-Type Systems for Systemic siRNA Delivery. Current Pharmaceutical Design, 2015, 21, 4541-4555.	0.9	13
105	Wheat Germ Agglutinin-Conjugated Nanoparticles for Sustained Cellular and Lung Delivery of Budesonide. Drug Delivery, 2008, 15, 81-86.	2.5	12
106	Polymer assisted entrapment of netilmicin in PLGA nanoparticles for sustained antibacterial activity. Journal of Microencapsulation, 2015, 32, 61-74.	1.2	12
107	cRGD Grafted siRNA Nano-constructs for Chemosensitization of Gemcitabine Hydrochloride in Lung Cancer Treatment. Pharmaceutical Research, 2015, 32, 806-818.	1.7	12
108	IGF-II-Conjugated Nanocarrier for Brain-Targeted Delivery of p11 Gene for Depression. AAPS PharmSciTech, 2019, 20, 50.	1.5	12

#	Article	IF	CITATIONS
109	Polymers in Drug Delivery: An Update. , 2021, , 1-42.		12
110	Clinical assessment of the combination therapy with liposomal gels of tretinoin and benzoyl peroxide in acne. AAPS PharmSciTech, 2001, 2, 1-5.	1.5	11
111	Aerosol Performance of Large Respirable Particles of Amikacin Sulfate Produced by Spray and Freeze Drying Techniques. Current Drug Delivery, 2009, 6, 8-16.	0.8	11
112	Optimization and efficacy study of synergistic vincristine coloaded liposomal doxorubicin against breast and lung cancer. Nanomedicine, 2020, 15, 2585-2607.	1.7	11
113	Pulmonary Absorption Enhancement of Salmon Calcitonin. Journal of Drug Targeting, 2004, 12, 135-144.	2.1	10
114	Formulation and Evaluation of Insulin Dry Powder for Inhalation. Drug Development and Industrial Pharmacy, 2006, 32, 677-686.	0.9	10
115	Role of lipid nanocarriers for enhancing oral absorption and bioavailability of insulin and GLP-1 receptor agonists. Journal of Drug Targeting, 2021, 29, 834-847.	2.1	10
116	Mathematical modelling of preparation of acyclovir liposomes: reverse phase evaporation method. Journal of Pharmacy and Pharmaceutical Sciences, 2002, 5, 285-91.	0.9	10
117	Influence of absorption promoters on pulmonary insulin bioactivity. AAPS PharmSciTech, 2003, 4, 32-43.	1.5	9
118	Gene Delivery Using Chemical Methods. , 2011, , 127-206.		9
119	Atopic Dermatitis: Drug Delivery Approaches in Disease Management. Critical Reviews in Therapeutic Drug Carrier Systems, 2015, 32, 323-361.	1.2	9
120	Protein and Peptide Delivery through Respiratory Pathway., 2011,, 429-479.		8
121	Development of Novel Lyophilized Mixed Micelle Amphotericin B Formulation for Treatment of Systemic Fungal Infection. Current Drug Delivery, 2005, 2, 177-184.	0.8	7
122	Transdermal Delivery of Macromolecules Using Nano Lipid Carriers. Current Pharmaceutical Design, 2021, 27, 4330-4340.	0.9	7
123	Synthesis and characterization of hindered-phenol-containing amine moieties as antioxidants for polypropylene copolymers. Journal of Applied Polymer Science, 2004, 91, 1097-1103.	1.3	6
124	Development of siRNA lipoplexes for intracellular delivery in lung cancer cells. Journal of Pharmacy and Bioallied Sciences, 2012, 4, 1.	0.2	6
125	Lipid based formulation approach for BCS class-II drug: Modafinil in the treatment of ADHD. Journal of Drug Delivery Science and Technology, 2017, 37, 166-183.	1.4	6
126	Development of aÂdry powder for inhalation of nanoparticles codelivering cisplatin and <i>ABCC3</i> siRNA in lung cancer. Therapeutic Delivery, 2021, 12, 651-670.	1.2	6

#	Article	IF	CITATIONS
127	siRNA: Sojourn from discovery to delivery challenges and clinics. Systematic Reviews in Pharmacy (discontinued), 2010, 1, 1.	0.6	5
128	Parenteral Delivery of Peptides and Proteins. , 2011, , 531-622.		5
129	Patents Review in siRNA Delivery for Pulmonary Disorders. Recent Patents on Drug Delivery and Formulation, 2012, 6, 45-65.	2.1	5
130	Polymers in Nasal Drug Delivery: An Overview. , 2021, , 305-332.		5
131	Abstract 2063: Improved sensitivity and in vitro efficacy of RGD grafted PEGylated gemcitabine liposomes in RRM1 siRNA pretreated cancer cells. , 2016, , .		5
132	Gene Delivery Using Viral Vectors. , 2011, , 207-270.		4
133	Inhalation therapy to treat pulmonary arterial hypertension. Pharmaceutical Patent Analyst, 2012, 1, 577-588.	0.4	4
134	Recent gene delivery patents for treatment of atherosclerosis. Pharmaceutical Patent Analyst, 2018, 7, 103-105.	0.4	4
135	Applications of Polymers in Parenteral Drug Delivery. , 2021, , 221-261.		4
136	Pulmonary absorption of liposomal levonorgestrel. AAPS PharmSciTech, 2004, 5, 96-100.	1.5	4
137	Dose Reduction of a Potent Topical Corticosteroid with Microemulsion Based Cream. Journal of Nanopharmaceutics and Drug Delivery, 2013, 1, 52-63.	0.3	4
138	Effect of Penetration Enhancers on Transdermal Absorption of Insulin Across Human Cadaver Skin. Drug Development and Industrial Pharmacy, 1994, 20, 2585-2591.	0.9	3
139	Other Routes of Protein and Peptide Delivery. , 2011, , 623-671.		3
140	Challenges and Opportunities in Gene Delivery. , 2011, , 45-82.		3
141	Development and evaluation of oral osmotic pump of butorphanol tartrate. Pharmaceutical Development and Technology, 2014, 19, 868-880.	1.1	3
142	Formulation and clinical perspectives of inhalation-based nanocarrier delivery: a new archetype in lung cancer treatment. Therapeutic Delivery, 2021, 12, 397-418.	1.2	3
143	Approaches and Recent Trends in Gene Delivery for Treatment of Atherosclerosis. Recent Patents on Drug Delivery and Formulation, 2016, 10, 141-155.	2.1	3
144	Systematic development and characterization of inhalable dry powder containing Polymeric Lipid Hybrid Nanocarriers co-loaded with ABCB1 shRNA and docetaxel using QbD approach. Journal of Drug Delivery Science and Technology, 2021, 66, 102903.	1.4	3

#	Article	IF	CITATIONS
145	Controlled Release Capsule of Tetracycline Hydrochloride. Drug Development and Industrial Pharmacy, 1989, 15, 825-844.	0.9	2
146	Synthesis and Characterization of Homologue of Irganox 1076—Some Novel Observations. Synthetic Communications, 2003, 33, 199-205.	1.1	2
147	Pharmacokinetic Evaluation of Wheat Germ Agglutinin-Grafted Nanoparticles of Mometasone Furoate. Scientia Pharmaceutica, 2009, 77, 123-132.	0.7	2
148	Applications of Gene Therapy., 2011,, 271-323.		2
149	Assessment of In-Vitro Antiproliferative Activity After Intracellular Drug Delivery from Wheat Germ Agglutinin-Conjugated Budesonide Nanoparticles. Journal of Biomedical Nanotechnology, 2007, 3, 61-67.	0.5	2
150	Inhalation Drug Therapy: Emerging Trends in Nasal and Pulmonary Drug Delivery., 2019,, 291-333.		2
151	Role of 99mTc-mannitol and 99mTc-PEG in the assessment of paracellular integrity of cell monolayers. Nuclear Medicine Communications, 2007, 28, 653-659.	0.5	1
152	Surfactants and Block Copolymers in Drug Delivery. Surfactant Science, 2010, , 1-53.	0.0	1
153	The Cell. , 2011, , 1-43.		1
154	Targeting Approaches Using Polymeric Nanocarriers., 2021,, 393-421.		1
155	Exploration of the cardinal formulation parameters influencing the encapsulation and physicochemical properties of co-loaded anticancer dual drug nanoliposomes. Journal of Drug Delivery Science and Technology, 2022, , 103295.	1.4	1
156	Refining a Research Manuscript. Journal of Young Pharmacists, 2010, 2, 213-215.	0.1	0
157	Abstract 2772: Biodistribution and pharmacokinetics of RGD grafted PLGA nanoparticles after radiolabling with 99mTC on tumor bearing rat model. , 2010 , , .		0
158	Abstract 3235: Improved in vitro efficacy study of RGD grafted docetaxel encapsulated solid lipid nanoparticles on breast cancer cells. , 2011, , .		O